Cohance Lifesciences
add_icon

Cohance Lifesciences

289.35
-2.35
(-0.81%)
Market Cap
11,069.58 Cr
PE Ratio
43.28
Volume
5,68,650.00
Day High - Low
293.95 - 282.25
52W High-Low
1,250.00 - 266.70
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
11,069.58 Cr
EPS
10.52
PE Ratio
43.28
PB Ratio
2.96
Book Value
99.01
EBITDA
433.80
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
14.38
Debt to Equity
0.09
Analyst Rating and Forecast
- By Refinitiv from8 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+62.50 %
+62.50 %
Hold
Hold+37.50 %
+37.50 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
JASUB Property Holdings LLP acquired 70,00,000 shares (1.83%) of Cohance Lifesciences through inter-se transfer block deals on February 18, 2026, as disclosed under SEBI regulations.
neutral
Jasti Property and Equity Holdings Private Limited, acting as trustee of Jasti Family Trust, disclosed a reduction in shareholding in Cohance Lifesciences Limited from 6.59% to 6.36% through open market and inter-se transfer transactions.
neutral
Cohance Lifesciences Limited has made available the audio recording of its quarterly conference call for Q3FY26 and nine months ended December 31, 2025, on its website.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,825.30
#1 4,37,950.61
39.98
#1 54,729.00
9.71
#1 10,980
16.07
70.29
6,282.00
1,66,767.36
67.99
9,712.00
18.67
2,191
-1.02
49.00
4,446.00
1,50,472.84
65.98
11,539.40
6.99
1,911
26.24
68.79
1,319.00
1,10,087.74
20.03
33,741.20
16.73
5,725
-15.28
59.78
2,357.30
1,07,681.18
22.96
22,909.50
13.74
3,306
#1 37.44
67.87
1,324.30
1,06,973.22
23.70
28,409.50
7.12
5,291
-57.18
43.23
916.90
92,261.59
#1 18.46
23,511.00
18.55
4,615
-0.32
52.66
2,207.90
91,143.23
51.36
12,744.20
#1 20.90
2,007
7.65
55.18
1,311.90
76,195.36
21.74
32,345.60
9.43
3,484
7.59
70.43
5,444.00
65,091.19
27.32
13,458.30
3.70
2,216
1.90
43.98

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
12.83 %
Net Income Growth
-11.82 %
Cash Flow Change
-19.62 %
ROE
-1.78 %
ROCE
-30.56 %
EBITDA Margin (Avg.)
-17.81 %

Quarterly Financial Results

Quarterly Financials
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
251
217
282
190
211
254
247
296
281
293
324
456
381
350
289
367
381
358
251
234
270
508
620
698
853
564
571
551
Expenses
129
95
147
99
108
126
140
138
166
149
179
206
207
188
179
207
198
181
133
154
180
363
398
439
627
445
435
454
EBITDA
122
122
135
91
103
128
107
158
116
144
144
251
174
162
111
160
183
178
118
80
90
145
222
259
226
118
137
97
Operating Profit %
49 %
52 %
46 %
45 %
41 %
47 %
41 %
50 %
36 %
43 %
40 %
48 %
43 %
45 %
36 %
41 %
47 %
48 %
42 %
30 %
29 %
26 %
34 %
35 %
25 %
19 %
22 %
17 %
Depreciation
6
6
6
6
7
7
8
9
8
9
9
11
10
12
12
12
12
13
12
13
17
31
38
44
54
45
44
47
Interest
2
4
4
8
7
3
3
2
2
2
1
1
2
2
0
1
5
1
1
2
2
10
10
11
10
10
9
9
Profit Before Tax
115
113
125
78
89
118
97
148
106
133
134
240
161
149
99
146
166
164
105
66
71
103
174
205
161
63
84
41
Tax
40
21
32
20
15
26
23
34
22
28
37
79
70
41
26
38
42
43
26
19
18
28
36
51
44
16
17
12
Net Profit
75
92
93
58
74
92
74
114
83
105
97
160
92
108
72
108
124
121
80
47
53
75
138
154
117
46
66
29
EPS in ₹
5.88
7.22
3.65
4.55
5.83
3.60
2.91
4.46
3.27
4.13
3.81
6.29
3.60
4.22
2.83
4.23
4.87
4.74
3.13
1.84
2.10
1.98
3.63
4.02
3.16
1.28
1.94
0.96

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
2025
Total Assets
783
1,173
1,475
1,830
1,966
2,254
3,032
Fixed Assets
271
357
441
534
663
670
1,713
Current Assets
390
392
565
1,128
1,011
1,263
889
Capital Work in Progress
111
102
96
30
165
179
256
Investments
7
338
542
598
536
905
337
Other Assets
394
376
395
667
601
501
726
Total Equity & Liabilities
783
1,173
1,475
1,830
1,966
2,254
3,032
Current Liabilities
158
200
220
210
159
107
365
Non Current Liabilities
35
128
74
92
72
97
826
Total Equity
590
845
1,181
1,527
1,735
2,051
1,841
Reserve & Surplus
578
832
1,155
1,502
1,710
2,025
1,671
Share Capital
13
13
26
26
26
26
26

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
11
1
-5
37
20
-18
38
Investing Activities
-66
-414
-311
-136
-195
-362
-253
Operating Activities
50
407
383
330
457
359
288
Financing Activities
26
7
-76
-156
-242
-14
3

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
May 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
50.10 %
50.10 %
50.10 %
50.10 %
50.10 %
66.41 %
66.41 %
57.49 %
57.49 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.01 %
10.14 %
9.54 %
9.80 %
10.70 %
10.84 %
11.05 %
7.38 %
7.23 %
6.51 %
6.02 %
DIIs
4.30 %
4.47 %
4.94 %
5.24 %
5.91 %
6.32 %
10.52 %
11.35 %
11.43 %
9.23 %
14.14 %
15.94 %
17.24 %
17.42 %
16.94 %
16.68 %
16.60 %
11.02 %
11.40 %
20.82 %
21.57 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
20.87 %
19.86 %
19.21 %
18.38 %
17.07 %
16.86 %
14.69 %
14.01 %
12.76 %
12.80 %
11.76 %
10.87 %
10.51 %
10.08 %
9.75 %
9.81 %
9.68 %
6.63 %
6.40 %
6.42 %
6.76 %
Others
14.84 %
15.68 %
15.86 %
16.38 %
17.02 %
16.82 %
14.78 %
14.64 %
15.81 %
17.97 %
4.08 %
3.04 %
12.59 %
12.59 %
12.50 %
12.56 %
12.55 %
8.55 %
8.55 %
8.75 %
8.16 %
No of Share Holders
75,207
92,534
96,532
86,447
85,725
86,088
82,577
79,412
72,885
72,167
73,715
70,052
68,932
65,777
69,337
84,210
86,325
88,658
80,910
75,284
81,877

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 5 2 5 6 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 1.01 0.32 1.06 0.89 0.00 0.00 0.00

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 24, 2026
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Feb 20, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 16, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2026
Outcome Of Board MeetingFeb 12, 2026
Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2026
Cohance Lifesciences Limited Has Informed The Exchange About Additional Information On USFDA Announcement.Feb 06, 2026
Cohance Lifesciences Limited Has Informed The Exchange About USFDA Announcement.Feb 04, 2026
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerFeb 02, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 22, 2026
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJan 22, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 22, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJan 19, 2026
Grant Of Stock OptionsJan 17, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Closure of Trading WindowDec 29, 2025
Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine-Months Ending December 31 2025Dec 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 24, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotDec 23, 2025
Intimation Of Change In Website Address Of The CompanyDec 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 05, 2025
Announcement under Regulation 30 (LODR)-Credit RatingDec 03, 2025
Grant Of Stock OptionsDec 03, 2025
General UpdatesDec 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2025
Outcome Of The MeetingNov 12, 2025
Board Meeting Outcome for Outcome Of The Board MeetingNov 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 28, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateOct 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
General UpdateOct 26, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Closure of Trading WindowSep 27, 2025
Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ending September 30 2025.Sep 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 24, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
UTI Nifty500 Shariah Index Fund Direct-Growth
0.09%
1957
0.09%
0.09%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.26%
1911
-0.06%
-0.17%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
0.26%
80
-0.06%
-0.16%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.09%
-39
-0.02%
-0.06%
DSP Nifty 500 Index Fund Direct-Growth
0.03%
-6
0.00%
0.03%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.02%
5
-0.01%
-0.02%
ICICI Prudential Active Momentum Fund Direct-Growth
0.00%
0
0.00%
0.00%
ITI Value Fund Direct - Growth
0.72%
0
0.00%
-0.17%
Angel One Nifty Total Market Index Fund Direct - Growth
0.02%
0
0.00%
-0.01%
Angel One Nifty Total Market Momentum Quality 50 Index Fund Direct - Growth
0.00%
0
0.00%
0.00%
Axis Equity Savings Fund Direct-Growth
0.00%
0
0.00%
-0.06%
Axis Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
-0.20%
Axis Focused Direct Plan-Growth
0.00%
0
0.00%
-0.44%
ICICI Prudential Innovation Fund Direct - Growth
0.86%
0
0.00%
-0.18%
Axis Innovation Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Midcap Direct Plan-Growth
0.04%
0
0.00%
-0.05%
Axis Momentum Fund Direct - Growth
0.00%
0
0.00%
0.00%
Axis Multicap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Nifty 500 Index Fund Direct-Growth
0.03%
0
0.00%
-0.01%
Axis Nifty500 Momentum 50 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Retirement Fund - Aggressive Plan Direct-Growth
0.18%
0
0.00%
-0.04%
Axis Retirement Fund - Dynamic Plan Direct-Growth
0.22%
0
0.00%
-0.05%
Axis Small Cap Fund Direct-Growth
0.15%
0
0.00%
-0.13%
Bajaj Finserv Healthcare Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Balanced Advantage Fund Direct-Growth
0.14%
0
0.00%
-0.04%

Technical Indicators

RSI(14)
Neutral
31.93
ATR(14)
Volatile
17.35
STOCH(9,6)
Neutral
26.01
STOCH RSI(14)
Neutral
79.33
MACD(12,26)
Bullish
3.10
ADX(14)
Strong Trend
41.39
UO(9)
Bearish
42.86
ROC(12)
Downtrend And Accelerating
-4.49
WillR(14)
Neutral
-61.24

About Cohance Lifesciences

Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more
Chairperson NameVivek Sharma